![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
ZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and...
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hoursHigh treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score...
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
Period β | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.94 | 5.26315789474 | 17.86 | 19.7 | 17.28 | 65721 | 18.79869207 | CS |
4 | -0.25 | -1.31233595801 | 19.05 | 20.88 | 15.37 | 79971 | 18.13015859 | CS |
12 | -3.81 | -16.8509509067 | 22.61 | 25.5 | 15.37 | 74539 | 20.25170133 | CS |
26 | -8.3 | -30.6273062731 | 27.1 | 33 | 15.37 | 91552 | 24.71956946 | CS |
52 | 3.48 | 22.7154046997 | 15.32 | 33 | 13.65 | 87732 | 23.13861997 | CS |
156 | 0.3 | 1.62162162162 | 18.5 | 33 | 1.77 | 219531 | 12.23011251 | CS |
260 | -6.2 | -24.8 | 25 | 42.86 | 1.77 | 203327 | 13.00940808 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions